🟡 60/100

Review before taking

  • Niacin: 250mg is 7.1× the Tolerable Upper Intake Level (35mg)
  • 100% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 250mg is 7.1× the Tolerable Upper Intake Level (35mg)

This product received a low safety score because the 250mg dose of niacin is more than seven times higher than the recommended maximum daily limit.

Label Data

1 Tablet(s) Serving Size
Vitamin Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

250 mg (1563% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 7.1× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 250mg UL 35mg

Other Ingredients

Dicalcium Phosphate Microcrystalline Cellulose Stearic Acid Croscarmellose Sodium Rice Bran Powder

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years) Kosher Gluten Free Dairy Free Sugar Free

Product Information

📋 Directions for Use

Directions: As a dietary supplement, take one or two tablets daily.

⚠️ Warnings & Precautions

Keep out of reach of children.

Warning: Consult your physician prior to using this product if you are pregnant, nursing, taking medication, or have a medical condition.

Discontinue use two weeks prior to surgery. Niacin may cause a temporary flushing reaction.

🧪 Formulation Notes

Supports a healthy blood lipid profile Supports blood vessel health

Potency verified by GNC procedure #5103. Conforms to USP <2091> for weight. Meets USP <2040> disintegration.

No sugar, no starch, no artificial colors, no artificial flavors, no preservatives, sodium free, no wheat, gluten free, no corn, no soy, no dairy.

Ko Kosher Service

GF Gluten free

Additional Information

Store in a cool, dry place.

100 servings

Ko Kosher Service

Product Details

UPC / SKU 0 48107 20582 9
DSLD Entry Date 2020-06-24
Product Type Vitamin
Form Tablet or Pill
Brand GNC
DSLD ID 224674
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →